Understand the source comparison
GHRP-2 Acetate: Research Peptide Comparison
GHRP-2 Acetate GHS-R1a agonist 30–45 min 20–30 min Minimal (10–15% increase) None to slight Best balance of GH amplitude and selectivity for protocols requiring pulsatile patterns without metabolic confounders GHRP-6 Moderate (30–40% increase) Significant incr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHRP-2 Acetate
- GHS-R1a agonist
- 30–45 min
- 20–30 min
- Minimal (10–15% increase)
- None to slight
- Best balance of GH amplitude and selectivity for protocols requiring pulsatile patterns without metabolic confounders
- GHRP-6
- Moderate (30–40% increase)
- Significant increase (ghrelin pathway activation)
- Higher GH output than GHRP-2 but appetite stimulation limits use in metabolic studies
- Ipamorelin
- GHS-R1a selective agonist
- 45–60 min
- 120 min
- None
- Most selective profile—ideal for isolating GH effects but lower anabolic response than GHRP-2
- CJC-1295 (no DAC)
- GHRH analog
- Amplifies natural pulses
- 30 min
- Synergistic with GHRP-2; use together for 3–4× GH amplitude vs either alone
- MK-677
- Oral ghrelin mimetic
- Continuous elevation
- 24 hours
- Moderate increase
- Convenient oral dosing but non-physiological flat GH curve; less effective for anabolic outcomes
- Hexarelin
- Moderate
- Slight
- Highest GH amplitude but CD36 receptor binding raises cardiac fibrosis concerns in long protocols
- The comparison shows GHRP-2 acetate occupies a middle position between maximal GH output (hexarelin, GHRP-6) and maximal selectivity (ipamorelin). The trade-off determines which peptide fits which research question: body composition studies favor GHRP-2's amplitude; neuroendocrine studies favor ipamorelin's selectivity; combined protocols use GHRP-2 plus CJC-1295 for multiplicative GH effects.